Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19041889 | 0.80 | MAP4K1 (0.39) | MAP4K1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL34470940 | 0.79 | MAP4K1 (0.38) | MAP4K1EGFRALDH1A1GAAMAPT | |
| SCHEMBL24723495 | 0.79 | MAP4K1 (0.38) | MAP4K1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL17630687 | 0.79 | MAP4K1 (0.38) | MAP4K1EGFRALDH1A1GAAMAPT | |
| SCHEMBL1191469 | 0.79 | ALDH1A1 (0.50) | MAP4K1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL21333463 | 0.77 | ALPL (0.46) | MAP4K1 | |
| SCHEMBL1190671 | 0.76 | TBK1 (0.39) | MAP4K1EGFRALDH1A1GAAMAPT | |
| SCHEMBL1191144 | 0.76 | EGFR (0.40) | MAP4K1EGFRALDH1A1GAAMAPT | |
| SCHEMBL21384956 | 0.75 | GRM5 (0.38) | MAP4K1EGFRALDH1A1GAAMAPT | |
| SCHEMBL22691605 | 0.75 | MAP4K1 (0.36) | MAP4K1ALDH1A1GAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-06-24 | — | — | US | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-111699189-B | Modulators of beta-3 adrenergic receptors useful for treating or preventing heart failure and disorders associated therewith | 艾尼纳制药公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-01-30 | — | — | US | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| EP-4482842-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN- 1 ACTIVITY | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110803-A | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101379044-A | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | MAP4K1 3634/4885EGFR 4567/4885ALDH1A1 312/4885 |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | MAP4K1 1655/4885EGFR 4022/4885ALDH1A1 4016/4885 |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | MAP4K1 4484/4885EGFR 4564/4885ALDH1A1 324/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | MAP4K1 4484/4885EGFR 4564/4885ALDH1A1 324/4885 |
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | HPGD, UGDH, PGD | MAP4K1 3167/4885EGFR 4440/4885ALDH1A1 83/4885 |
| US-12338255-B2 | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MAP4K1 3061/4885EGFR 4451/4885ALDH1A1 698/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | MAP4K1 4484/4885EGFR 4564/4885ALDH1A1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.